Lyric is developing novel therapeutics to improve the care of critically ill and hospitalized patients. Lyric’s lead program, an intravenous pro-kinetic and pro-metabolic drug candidate, is currently under Phase 2 study for the treatment of enteral feeding intolerance in the intensive care unit, an unmet medical need associated with significant morbidity and mortality.